

PACKAGE INSERT

FUNGIFEX

PRODUCT NAME

Fungifex 250 mg tablets

NAME AND STRENGHT OF ACTIVE SUBSTANCE

Each tablet contains terbinafine hydrochloride equivalent to 250 mg terbinafine.

For the full list of excipients, see section List of excipients.

PRODUCT DESCRIPTION

Tablet.

White to off-white, round tablets with Remedica logo on the scored side and engraved with the letter 'T' on the other.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Pharmacotherapeutic group: Antifungals for dermatological use, Antifungals for systemic use, ATC code: D01BA02

Mechanism of action (MOA)

Terbinafine is an allylamine which has a broad spectrum of activity against fungal pathogens of the skin, hair and nails including dermatophytes such as *Trichophyton* (e.g. *T. rubrum*, *T. mentagrophytes*, *T. verrucosum*, *T. tonsurans*, *T. violaceum*), *Microsporum* (e.g. *M. canis*), *Epidermophyton floccosum*, and yeasts of the genera *Candida* (e.g. *C. albicans*) and *Malassezia*. At low concentrations terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi. Its activity against yeasts is fungicidal or fungistatic, depending on the species.

Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death. Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane. The enzyme squalene epoxidase is not linked to the cytochrome P450 system.

When given orally, terbinafine accumulates in skin, hair and nails at levels associated with fungicidal activity.

Pharmacokinetic properties

Absorption

Following oral administration, terbinafine is well absorbed (>70%) A single oral dose of 250 mg terbinafine resulted in mean peak plasma concentrations of 1.30 µg/ml within 1.5 hours after administration. At steady state (70% steady state is achieved in approximately 28 days), in comparison to a single dose, peak concentration of terbinafine was on average 25 % higher and plasma AUC increased by a factor of 2.3.

Distribution

Terbinafine binds strongly to plasma proteins (99%). It rapidly diffuses through the dermis and accumulates in the lipophilic stratum corneum. Terbinafine is also secreted in sebum, thus achieving high concentrations in hair follicles, hair and sebum-rich skins. There is also evidence that terbinafine is distributed into the nail plate within the first few weeks of commencing therapy.

Biotransformation/Metabolism

Terbinafine is metabolized rapidly and extensively by at least seven CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19. Biotransformation results in metabolites with no antifungal activity.

Elimination

The metabolites are excreted predominantly in the urine. From the increase in plasma AUC at steady state an effective half-life of ~ 30 hours was calculated. Multiple dose administration followed by extended blood sampling revealed a triphasic elimination with a terminal half-life of approximately 16.5 days.

Bioavailability

The absolute bioavailability of terbinafine from terbinafine tablets as a result of first-pass metabolism is approximately 50%.

Special populations

No clinically relevant age-dependent changes in steady-state plasma concentrations of terbinafine have been observed.

Single dose pharmacokinetic studies in patients with renal impairment (creatinine clearance <50 ml/min) or with pre-existing liver disease have shown that clearance of terbinafine may be reduced by about 50%.

Preclinical safety data

Repeat dose toxicity

In long-term studies (up to 1 year) in rats and dogs no marked toxic effect were seen in either species up to oral doses of about 100 mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.

In a 32-week repeated dose study in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level 50 mg/kg/day). These irregularities were associated with the presence of a terbinafine metabolite in ocular tissue and disappeared after drug discontinuation. They were not associated with histological changes. In 4-week studies, intravenous administration of terbinafine resulted in central nervous system disturbances including hypoactivity, ataxia and convulsions in rats (> 30 mg/kg/day) and monkeys (75 mg/kg/day).

Mutagenicity and carcinogenicity

A standard battery of *in vitro* and *in vivo* genotoxicity tests revealed no evidence of mutagenic or clastogenic potential.

In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 156 (females) mg/kg a day. In a two-year oral carcinogenicity study in rats, an increased incidence of liver tumours was observed in males at the highest dosage level of 69 mg/kg a day. The changes which may be associated with peroxisome proliferation have been shown to be species-specific since they were not seen in the carcinogenicity study in mice, dogs or monkeys.

Reproductive toxicity

In a fertility and reproductive study, rats were treated orally with terbinafine (10, 50, or 250 mg/kg/day) starting 9 weeks (males) or 2 weeks (females) prior to mating and continued through pregnancy and lactation. There were no effects on fertility or general reproductive performance. However at 250 mg/kg/day (corresponding to 10 times the MRHD based on BSA), there was evidence of parental toxicity (reduced body weight gain, lower pregnancy rate and litter size), increased pre- and perinatal offspring mortality, and retarded postnatal offspring development. For information on embryofetal and pre- and postnatal toxicity, see section Pregnancy, Lactation, Females and Males of Reproductive Potential.

Juvenile animal studies

An 8-week oral study in juvenile rats provided a no-toxic-effect level (NTEL) of close to 100 mg/kg/day, with the only finding being slightly increased liver weights, while in maturing dogs at \geq 100 mg/kg/day (AUC values about 13x (m) and 6x (f) those in children), signs of central nervous system (CNS) disturbance including single episodes of convulsions in individual animals were observed. Similar findings have been observed at high systemic exposure upon intravenous administration of terbinafine to adult rats or monkeys.

CLINICAL STUDIES

Onychomycosis

The efficacy of terbinafine in the treatment of onychomycosis is illustrated by the response of patients with toenail and/or fingernail infections who participated in three US/Canadian placebo-controlled clinical trials (SFD301, SF5 and SF1508).

Results of the first toenail study, as assessed at week 48 (12 weeks of treatment with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 70% of patients. Fifty-nine percent (59%) of patients experienced effective treatment (mycological cure plus 0% nail involvement or >5mm of new unaffected nail growth); 38% of patients demonstrated mycological cure plus clinical cure (0% nail involvement).

In a second toenail study of dermatophytic onychomycosis, in which non-dermatophytes were also cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic role of the non-dermatophytes cultured in the presence of dermatophytic onychomycosis has not been established. The clinical significance of this association is unknown.

Results of the fingernail study, as assessed at week 24 (6 weeks of treatment with 18 weeks follow-up after completion of therapy), demonstrated mycological cure in 79% of patients, effective treatment in 75% of the patients, and mycological cure plus clinical cure in 59% of the patients.

The mean time to treatment success for onychomycosis was approximately 10 months for the first toenail study and 4 months for the fingernail study. In the first toenail study, for patients evaluated at least six months after achieving clinical cure and at least one year after completing terbinafine therapy, the clinical relapse rate was approximately 15%.

Tinea capitis

In the three comparative efficacy studies SF 8001, SFE 304, SF 8002 oral terbinafine (62.5 – 250 mg daily) was given to a total of 117 evaluable patients, of whom over 95% were children. Single daily doses were given after the evening meal for 4 weeks (terbinafine) or 8 weeks (griseofulvin). Efficacy, demonstrated by negative mycology tests and a reduction in symptomatology, was evaluated at 8 weeks and at the follow-up examination (Week 12 for Studies SF 8001 and SFE 304, Week 24 for Study SF 8002). Negative mycology test results at follow-up were achieved by 93%, 88% and 72% of patients given terbinafine in the three studies – the corresponding figures for griseofulvin were 88%, 89% and 69%. The derived variable “effective treatment” (negative mycology plus no, or only mild, symptoms and signs) was achieved in 82%, 78% and 69% of terbinafine-treated patients, compared with 66%, 74% and 59% in patients given griseofulvin; the difference was statistically significant in favor of terbinafine in Study SF 8001.

A 12-week randomized, double-blind, parallel group study was conducted in the United States and in Canada in children with Tinea capitis infection due to *Trichophyton* species (SFO327C T201). The objective of the study was to determine the optimal duration (1, 2 or 4 weeks) and safety of treatment with terbinafine (tablets), given at weight adjusted doses once daily. The primary efficacy criterion, Complete Cure at end of study, increased as terbinafine treatment duration increased (1 week, 42%, 2 weeks, 49.1% and 4 weeks, 55.6) however, differences between treatment groups were not significant. Terbinafine 1-week treatment group showed the least efficacy throughout the study for all efficacy variables.

Fungal infections of the skin (Tinea corporis, Tinea cruris, Tinea pedis) and yeast infections of the skin caused by the genus *Candida* (e.g. *Candida albicans*) where oral therapy is generally considered appropriate owing to the site, severity or extent of the infection

One multicenter, double blind, randomized placebo controlled study (6-7OR) evaluated the efficacy and safety of terbinafine in the treatment of Tinea corporis and cruris and two double blind randomized studies (5OR and 11-21OR(multicenter)), evaluated the efficacy and safety of terbinafine tablets in the treatment of Tinea corporis.

Two double blind, placebo controlled studies (5OR, 6-7OR) evaluated the efficacy of terbinafine 125mg b.i.d. in patients diagnosed with Tinea corporis/cruris. The studies included a total of 46 patients randomised to terbinafine and 49 on placebo. There was no significant difference in terms of demographic and anamnestic data within groups. Efficacy, demonstrated by negative mycology tests and a reduction in clinical symptomatology, was evaluated at 4 weeks and at the follow-up examination. In both studies, minimal efficacy was demonstrated in patients treated with placebo compared to the efficacy of orally administered terbinafine at the end of therapy and at follow up.

The third study (11-21OR), a 6 weeks, double blind, randomised, multicenter study compared efficacy and safety of terbinafine 125mg b.i.d. to griseofulvin 250mg b.i.d. One hundred twenty six (126) patients in each group were included in the efficacy analysis.

Effective therapy (microscopy and culture negative and no or minimal signs and symptoms) for Terbinafine Vs Griseofulvin were 93% Vs 87% at end of therapy and 94% Vs 86% at follow-up.

In a double blind, placebo controlled 4 weeks study SF 00438, terbinafine 125 b.i.d was compared to placebo in patients with cutaneous candidiasis. Twenty two patients were randomised to each treatment arm, of which 19 were evaluated respectively. At week 4 follow-up, a significantly greater proportion of patients in the terbinafine group were "Effectively" treated (negative mycology and minimal or no signs and symptoms) ($p = 0.029$). In the terbinafine group, 9/19 (47%) patients were "Effectively" treated compared to 2/19 (11%) in the placebo group. 29% of patients in the treatment arm and 17% of patients on placebo demonstrated negative mycology at the end of treatment and 67% of terbinafine treated patients had negative mycological results at the end of follow up compared to 47% for placebo.

Two double blind, controlled studies compared terbinafine 125mg b.i.d. to placebo (39-40OR) and to griseofulvin 250mg b.i.d. (20OR) in the treatment of Tinea pedis. In the study 39-40OR, 65% of patients on terbinafine reported effective treatment (negative mycology and minimal or no signs and symptoms) at follow up whereas none of the placebo treated patients responded. In the study 20OR, terbinafine was shown to be effective in 88% of patients at follow up after 6 weeks therapy compared to 45% of patients on griseofulvin.

Major efficacy studies – Tinea corporis/cruris, Tinea pedis, Candida infections

Study	Type	Drug	No. of evaluable patients	Dropouts	Mycological results % negative		Clinical results	
					End Rx	F/up	End Rx	F/up
5OR	4wk DB-placebo	Terbinafine 125 b.i.d Placebo	13 15	4 2	64 0	89 0	54 0	62 0
6-7OR	4wk DB-placebo	Terbinafine 125 b.i.d Placebo	33 34	8 6	97 29	97 36	85 12	91 12
11-21OR	6wk 125 b.i.d. DB-Griseofulvin	Terbinafine 125 b.i.d Griseofulvin 250 b.i.d	126 126	13 16	98 88	100 94	93 87	94 86
SF 00438	2wk DB-placebo	Terbinafine 125 b.i.d Placebo	19 19	3 3	29 17	67 47	11 11	47 11
39-40OR	6wk 125 b.i.d. DB-placebo	Terbinafine 125 b.i.d Placebo	23 18	3 6	68 13	77 0	59 0	65 0
20OR	6wk 125 b.i.d. DB-Griseofulvin	Terbinafine 125 b.i.d Griseofulvin 250 b.i.d	16 12	2 6	94 27	100 55	75 27	88 45

NON-CLINICAL SAFETY DATA

Repeat dose toxicity

In long-term studies (up to 1 year) in rats and dogs no marked toxic effects were seen in either species up to oral doses of about 100 mg/kg/day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.

In a 32-week repeated dose study in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level 50 mg/kg/day). These irregularities were associated with the presence of a terbinafine metabolite in ocular tissue and disappeared after drug discontinuation. They were not associated with histological changes. In 4-week studies, intravenous administration of terbinafine resulted in central nervous system disturbances including hypoactivity, ataxia and convulsions in rats (> 30 mg/kg/day) and monkeys (75 mg/kg/day)

Mutagenicity and carcinogenicity

A standard battery of *in vitro* and *in vivo* genotoxicity tests revealed no evidence of mutagenic or clastogenic potential.

In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 156 (females) mg/kg a day. In a two-year oral carcinogenicity study in rats, an increased incidence of liver tumors was observed in males at the highest dose level of 69 mg/kg a day. The changes, which may be associated with peroxisome proliferation have been shown to be species-specific since they were not seen in the carcinogenicity study in mice or in other studies in mice, dogs or monkeys.

Reproductive toxicity

In a fertility and reproductive study, rats were treated orally with terbinafine (10, 50, or 250 mg/kg/day) starting 9 weeks (males) or 2 weeks (females) prior to mating and continued through pregnancy and lactation. There were no effects on fertility or general reproductive performance. However at 250 mg/kg/day (corresponding to 10 times the MRHD based on BSA), there was evidence of parental toxicity (reduced body weight gain, lower pregnancy rate and litter size), increased pre- and perinatal offspring mortality, and retarded postnatal offspring development. For information on embryofetal and pre- and postnatal toxicity, see section Pregnancy, Lactation, Females and Males of Reproductive Potential.

Juvenile animal studies

An 8-week oral study in juvenile rats provided a no-toxic-effect level (NTEL) of close to 100 mg/kg/day, with the only finding being slightly increased liver weights, while in maturing dogs at ≥ 100 mg/kg/day (AUC values about 13x (m) and 6x (f) those in children), signs of central nervous system (CNS) disturbance including single episodes of convulsions in individual animals were observed. Similar findings have been observed at high systemic exposure upon intravenous administration of terbinafine to adult rats or monkeys.

CLINICAL PARTICULARS

Indications

Treatment of:

- Onychomycosis (fungal infection of the nail) caused by dermatophyte fungi.
- Tinea capitis.
- Fungal infections of the skin (Tinea corporis, Tinea cruris, Tinea pedis) and yeast infections of the skin caused by the genus *Candida* (e.g. *Candida albicans*) where oral therapy is generally considered appropriate owing to the site, severity or extent of the infection.

Oral terbinafine is not effective in Pityriasis versicolor (also known as Tinea versicolor).

Dosage and method of administration

Adults

250 mg once daily.

Skin infections

Recommended duration of treatment:

- Tinea pedis (interdigital, plantar / moccasin type): 2 to 6 weeks
- Tinea corporis, T. cruris: 2 to 4 weeks
- Cutaneous candidiasis: 2 to 4 weeks.

Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.

The duration of treatment varies according the indication and the severity of the infection.

Hair and scalp infections

Recommended duration of treatment:

- Tinea capitis: 4 weeks.

Tinea capitis occurs primarily in children.

Onychomycosis

For most patients the duration of successful treatment is 6 to 12 weeks.

Fingernail onychomycosis

Six weeks of therapy is sufficient for fingernail infections in most cases.

Toenail onychomycosis

Twelve weeks of therapy is sufficient for toenail infections in most cases.

Some patients with poor nail outgrowth may require longer treatment. The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail.

Special populations

Hepatic impairment

Terbinafine is contraindicated for patients with chronic or active hepatic disease (see sections Contraindications and Special warnings and precautions for use).

Renal impairment

The use of terbinafine has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section Special warnings and precautions for use and section Pharmacokinetic properties).

Geriatric Patients

There is no evidence to suggest that elderly patients (aged 65 years or above) require different dosages or experience different side effects than younger patients. When prescribing Fungifex for patients in this age group, the possibility of impairment of liver or kidney function should be considered (see Precautions).

Pediatric Patients

No data are available in children under two years of age (usually <12 kg).

Children weighing <20 kg	62.5 mg	(half a 125 mg tablet) once daily
Children weighing 20 to 40 kg	125 mg	(one 125 mg tablet) once daily
Children weighing >40 kg	250 mg	(two 125 mg tablets) once daily

Method of administration

The scored tablets are taken orally with water. They should preferably be taken at the same time each day and can be taken on an empty stomach or after a meal.

Contraindications

- Known hypersensitivity to terbinafine or to any of the excipients of Fungifex.
- Chronic or active hepatic disease.

Warnings and precautions

Liver function

Terbinafine is contraindicated for patients with chronic or active hepatic disease. Before prescribing Fungifex, liver function tests should be performed. Since hepatotoxicity may occur in patients with and without pre-existing liver disease. Therefore periodic monitoring (after 4-6 weeks of treatment) of liver function test is recommended. Terbinafine should be immediately discontinued in case of elevation of liver function test.

Very rare cases of serious liver failure (some with fatal outcome, or requiring liver transplant) have been reported in patients treated with terbinafine. In the majority of hepatic failure cases the patients had serious underlying systemic conditions (see section Contraindications and Adverse effects). Patients prescribed Fungifex should be warned to report immediately any symptoms of unexplained persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, or jaundice, dark urine or pale feces. Patients with these symptoms should discontinue taking oral terbinafine and the patient's liver function should be immediately evaluated.

Dermatological effects

Serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms) have been very rarely reported in patients taking terbinafine. If progressive skin rash occurs, Fungifex treatment should be discontinued.

Fungifex should be used with caution in patients with pre-existing psoriasis or lupus erythematosus as precipitation and exacerbation of psoriasis and cutaneous and systemic lupus erythematosus have been reported in a post-marketing setting.

Haematological effects

Very rare cases of blood dyscrasias (neutropenia, agranulocytosis, thrombocytopenia, pancytopenia) have been reported in patients treated with terbinafine. Etiology of any blood dyscrasias that occur in patients treated with Fungifex should be evaluated and consideration should be given for a possible change in medication regimen, including discontinuation of treatment with Fungifex.

Renal function

In patients with renal impairment (creatinine clearance less than 50 mL/min or serum creatinine of more than 300 micro mol/L) the use of terbinafine has not been adequately studied, and therefore, is not recommended (see section Pharmacokinetic properties).

Interactions

In vitro and *in vivo* studies have shown that terbinafine inhibits the CYP2D6 metabolism. Therefore, patients receiving concomitant treatment with drugs predominantly metabolized by CYP2D6, e.g. certain members of the following drug classes, tricyclic antidepressants (TCAs), beta-blockers, selective serotonin reuptake inhibitors (SSRIs), antiarrhythmics (including class 1A, 1B and 1C) and monoamine oxidase inhibitors (MAO-Is) Type B, should be followed up, especially if the co-administered drug has a narrow therapeutic window (see section Interactions).

Other

Fungifex contains sodium.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

Observed interactions to be considered

Interactions affecting the use of terbinafine

The plasma clearance of terbinafine may be accelerated by drugs which induce metabolism and may be inhibited by drugs, which inhibit cytochrome P450. Where co-administration of such agents is necessary, the dosage of Fungifex may need to be adjusted accordingly.

The following medicinal products may increase the effect or plasma concentration of terbinafine:

Cimetidine decreased the clearance of terbinafine by 33%.

Fluconazole increased the C_{max} and AUC of terbinafine by 52% and 69% respectively, due to inhibition of both CYP2C9 and CYP3A4 enzymes. Similar increase in exposure may occur when other drugs which inhibit both CYP2C9 and CYP3A4 such as ketoconazole and amiodarone are concomitantly administered with terbinafine.

The following medicinal products may decrease the effect or plasma concentration of terbinafine:

Rifampicin increased the clearance of terbinafine by 100%.

Interactions resulting in effects of terbinafine on other medicinal products

Terbinafine may increase the effect or plasma concentration of the following medicinal products:

Compounds predominantly metabolised by CYP2D6

In vitro and *in vivo* studies have shown that terbinafine inhibits the CYP2D6-mediated metabolism. This finding may be of clinical relevance for compounds predominantly metabolised by CYP2D6, e.g. certain members of the following drug classes, tricyclic antidepressants (TCA's), beta-blockers, selective serotonin reuptake inhibitors (SSRIs), antiarrhythmics (including class 1A, 1B and 1C) and monoamine oxidase inhibitors (MAO-Is) Type B, especially if they also have a narrow therapeutic window (see section Warnings and Precautions).

Terbinafine decreased the clearance of desipramine by 82% (see section Warnings and precautions).

In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increased the dextromethorphan/dextrorphan metabolic ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolizers (genotype) to poor metabolizer phenotype status.

Caffeine

Terbinafine decreased the clearance of caffeine administered intravenously by 19%.

Information on other drug concomitantly used with terbinafine resulting in no or negligible interactions.

According to the results from studies undertaken *in vitro* and in healthy volunteers, terbinafine shows negligible potential for inhibiting or enhancing the clearance of most drugs that are metabolized via other cytochrome P450 enzymes (e.g., terfenadine, triazolam, tolbutamide or oral contraceptives) with exception of those metabolized through CYP2D6 (see above).

Terbinafine does not interfere with the clearance of antipyrine or digoxin.

There was no effect of terbinafine on the pharmacokinetics of fluconazole. Further there was no clinically relevant interaction between terbinafine and the potential co-medication cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline.

Some cases of menstrual irregularities have been reported in patients taking terbinafine concomitantly with oral contraceptives, although the incidence of these disorders remains within the background incidence of patients taking oral contraceptives alone.

Terbinafine may decrease the effect of plasma concentration of the following medicinal products:

Terbinafine increased the clearance of cyclosporine by 15%.

Drug-food/ drink interactions

The bioavailability of terbinafine is moderately affected by food (increase in the AUC of less than 20%), but not sufficiently to require dose adjustments.

Pregnancy, Lactation, Females and Males of Reproductive Potential

Pregnancy

Risk Summary

There are no adequate or well-controlled clinical trials using terbinafine in pregnant women. In an observational, registry-based cohort study, there was no increase in the risk of major malformations or spontaneous abortion in pregnancies exposed to oral terbinafine in comparison to those not exposed to oral terbinafine (see Human Data).

In animal reproduction studies, terbinafine did not cause reproductive toxicity in rats and rabbits at oral doses up to 12 and 23 times the maximum recommended human dose (MRHD) based on body surface (BSA), respectively (see Animal Data).

The use of terbinafine maybe considered during pregnancy, if necessary.

Data

Human data

A nationwide, observational, registry-based cohort study was conducted in Denmark from January 1, 1997 to December 31, 2016 in a cohort of 1,650,649 pregnancies. Pregnancies were matched on propensity scores comparing pregnancies exposed to oral terbinafine versus those not exposed to oral terbinafine in a 1:10 ratio to evaluate the risk of major malformations (522 versus 5220) and spontaneous abortions (891 versus 8910).

The prevalence odds ratio for the risk of major malformations was 1.01 (95% CI, 0.63-1.62) for pregnancies exposed versus not exposed to oral terbinafine. The hazard ratio for the risk of spontaneous abortion was 1.06 (95% CI, 0.86-1.32) for the same comparison. No increased risk of major malformations or spontaneous abortion was identified among pregnancies exposed to oral terbinafine.

Animal data

In embryo-fetal development studies in rats and rabbits, terbinafine was administered orally (30, 100, or 300 mg/kg/day) during the period of organogenesis. There were no embryotoxic or teratogenic effects up to the maximum tested dose of 300 mg/kg/day in rats and rabbits (corresponding to 12 and 23 times the MRHD based on BSA, respectively). Subcutaneous administration of terbinafine (10, 30 or 100 mg/kg/day) to rats during the period of organogenesis showed no teratogenic or embryotoxic effect up at doses up to 100 mg/kg/day (corresponding to 4 times the MRHD based on BSA).

In a rat peri-and postnatal development study, oral administration of terbinafine (30, 100 or 300 mg/kg/day) had no adverse effects on pregnancy and lactation at doses up to 300 mg/kg/day (corresponding to 12 times the MRHD based on BSA). No treatment related effects in F1 and F2 generations were noted.

Lactation

Risk summary

Terbinafine is transferred into human breast milk. There are no data on the effects of terbinafine on the breastfed child or on milk production. The maximum ratio of terbinafine in milk to plasma is 7:1, and the maximum amount of terbinafine ingested by the infant is expected to be 16% of the dose administered to the nursing mother. The highest concentration of terbinafine in breast milk was observed within 6 hours after administration, and thereafter the concentration of terbinafine decreased by approximately 70% in the 6-12 hour time window after administration.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for terbinafine and any potential adverse effects on the breast-fed child from terbinafine.

Females of reproductive potential

There are no data to support special recommendations for women of child-bearing potential.

Infertility

There is no relevant information from human experience. Fertility studies in rats indicated no adverse findings in fertility or reproductive performance (see section Non-clinical safety data).

Effects on ability to drive and use machines

No studies on the effects of terbinafine treatment on the ability to drive and use machines have been performed. Patients who experience dizziness as an undesirable effect should avoid driving vehicles or using machines.

Adverse effects

Adverse drug reactions from clinical trials or post-marketing experience (Table 1) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency group, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III):

Very common	(\geq 1/10)
Common	(\geq 1/100, < 1/10)
Uncommon	(\geq 1/1,000, < 1/100)
Rare	(\geq 1/10,000, < 1/1,000)
Very rare	(<1/10,000)

Not known (frequency cannot be estimated from available data) including isolated reports.

Blood and lymphatic system disorders	
Uncommon	Anaemia
Very rare	Neutropenia, agranulocytosis, thrombocytopenia, pancytopenia.
Immune system disorders	
Very rare	Anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus.
Psychiatric disorders	
Common	Depression
Uncommon	Anxiety
Nervous system disorders	
Very common	Headache
Common	Dysgeusia* including ageusia*, dizziness
Uncommon	Paresthesia and hypoesthesia
Eye disorders	
Common	Visual impairment
Ear and labyrinth disorders	

Uncommon	Tinnitus.
Gastrointestinal disorders	
Very common	Gastrointestinal symptoms (abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea).
Hepatobiliary disorders	
Rare	Hepatic failure, hepatitis, jaundice, cholestasis, hepatic enzyme increased (see section Warnings and Precautions)
Skin and subcutaneous tissue disorders	
Very common	Rash, urticaria.
Uncommon	Photosensitivity reaction
Very rare	Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin eruption, dermatitis exfoliative, dermatitis bullous. Psoriasisiform eruptions or exacerbation of psoriasis. Alopecia.
Musculoskeletal and connective tissue disorders	
Very common	Musculoskeletal reactions (arthralgia, myalgia).
General disorders and administration site conditions	
Uncommon	Pyrexia
Common	Fatigue.
Investigations	
Uncommon	Weight decreased**.

**weight decreased secondary to dysgeusia

Adverse drug reaction from spontaneous report and literature cases (frequency not know)

The following adverse drug reactions have been derived from post-marketing experience with terbinafine via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classed in MedDRA. Within each system organ class, ADRs are presented in order to decreasing seriousness.

Adverse drug reaction from spontaneous report and literature cases (frequency not know)
Immune system disorders
Anaphylactic reaction, serum sickness-like reaction.
Nervous system disorders
Anosmia including permanent anosmia, hyposmia.
Eye disorders

Vision blurred, visual acuity reduced.
Ear and labyrinth disorders
Hypoacusis, hearing impaired.
Vascular disorders
Vasculitis.
Gastrointestinal disorders
Pancreatitis
Skin and subcutaneous tissue disorders
Drug rash with eosinophilia and systemic symptoms.
Musculoskeletal and connective tissue disorders
Rhabdomyolysis.
General disorder and administration site conditions
Influenza like illness.
Investigations
Blood creatine phosphokinase increased

Overdose

A few cases of overdose (up to 5 g) have been reported, giving rise to headache, nausea, epigastric pain and dizziness.

The recommended treatment of overdosage consists of eliminating the drug, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy, if needed.

PHARMACEUTICAL PARTICULARS

List of excipients

Cellulose, microcrystalline
 Silica, colloidal anhydrous
 Hypromellose
 Sodium starch glycolate (Type A)
 Magnesium stearate
 Water, purified

Incompatibilities

None known.

Shelf life

3 years.

Storage conditions

Do not store above 30°C. Protect from light and moisture.

Keep out of the reach and sight of children.

Presentation

Cardboard box containing Aluminium-PVC/PVDC blisters of 7 tablets.
Pack size of 14 tablets.

Manufacturer

Remedica Ltd.
Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus

Product registrant

Goldplus Universal Pte Ltd
103 Kallang Avenue
#06-02
Singapore 339504

Date of revision of the text

For internal use only: sg-pi-fungifex-tabs-a5